Nektar Therapeutics (NKTR) Cash & Equivalents (2010 - 2026)
Nektar Therapeutics (NKTR) posted quarterly Cash & Equivalents of $149.6 million for Q1 2026, up 284.58% year-over-year from $38.9 million in Q1 2025, and up 889.53% quarter-over-quarter from $15.1 million in Q4 2025.
Nektar Therapeutics (NKTR) Cash & Equivalents (2010 - 2026) Analysis & Trends
Nektar Therapeutics' Cash & Equivalents history runs 17 years deep, the most recent figure standing at $149.6 million for Q1 2026.
- In Q1 2026, Cash & Equivalents rose 284.58% year-over-year to $149.6 million; the TTM figure through Mar 2026 stood at $149.6 million (up 284.58% YoY), while the FY2025 annual figure was $15.1 million, down 65.84% from the prior year.
- Cash & Equivalents for Q1 2026 stood at $149.6 million, up from $15.1 million in the prior quarter.
- The five-year high for Cash & Equivalents was $149.6 million in Q1 2026, with the low at $15.1 million in Q4 2025.
- The 5-year median for Cash & Equivalents is $48.6 million (2024), against an average of $59.2 million.
- The sharpest annual moves came in 2025 and 2026: Cash & Equivalents plunged 65.84% in 2025, then surged 284.58% in 2026.
- Nektar Therapeutics' Cash & Equivalents stood at $88.2 million in 2022, then plunged by 60.02% to $35.3 million in 2023, then gained by 25.44% to $44.3 million in 2024, then plunged by 65.84% to $15.1 million in 2025, then soared by 889.53% to $149.6 million in 2026.
- Business Quant data shows NKTR's Cash & Equivalents at $149.6 million in Q1 2026, $15.1 million in Q4 2025, and $41.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 6.14 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.46 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 3.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 815.44 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.37 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 811.99 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.71 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 544.80 Mn |
| 10 | Nektar Therapeutics | 1.49 Bn | 919.46 Mn | 3.16 Mn | 149.58 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 149.58 Mn |
| Dec 31, 2025 | 15.12 Mn |
| Sep 30, 2025 | 41.03 Mn |
| Jun 30, 2025 | 42.99 Mn |
| Mar 31, 2025 | 38.89 Mn |
| Dec 31, 2024 | 44.25 Mn |
| Sep 30, 2024 | 30.11 Mn |
| Jun 30, 2024 | 27.94 Mn |
| Mar 31, 2024 | 48.64 Mn |
| Dec 31, 2023 | 35.28 Mn |
| Sep 30, 2023 | 64.92 Mn |
| Jun 30, 2023 | 50.73 Mn |
| Mar 31, 2023 | 76.96 Mn |
| Dec 31, 2022 | 88.23 Mn |
| Sep 30, 2022 | 105.76 Mn |
| Jun 30, 2022 | 77.55 Mn |
| Mar 31, 2022 | 67.99 Mn |
| Dec 31, 2021 | 25.22 Mn |
| Sep 30, 2021 | 54.02 Mn |
| Jun 30, 2021 | 152.35 Mn |